ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan Drug Designation
ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical-stage drug candidates at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 - June 2, 2009 in Orlando, Florida. Presentations include both poster and discussion sessions and are listed below.
- Poster Session: Friday, May 29, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No.: 3520, 'An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer.'
- Discussion Session: Friday, May 29, 2009 - 5:00 p.m. - 5:15 p.m. 'Angiogenesis Inhibitors: New Agents and New Combinations,' Level 4, Valencia Room, W415D.
- Poster Session: Saturday, May 30, 2009 - 8:00 a.m. - 12:00 p.m. Abstract No.: 3562, 'A single center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients with advanced cancer.'
- Poster Session: Sunday, May 31, 2009 - 2:00 p.m. - 6:00 p.m. Abstract No: 5577, 'Phase 2 study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.'
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
The Company has further expanded its clinical development efforts for ENMD-2076 and has commenced a Phase 1 study in patients with relapsed or refractory leukemia. The study will be conducted at the Princess Margaret Hospital in Toronto, Ontario and Karen Yee, M.D., will serve as Principal Investigator. Although the primary endpoints of the study include defining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 administered orally in patients with relapsed or refractory leukemia, the study will also evaluate pharmacodynamic effects of ENMD-2076 by collaborating with Dr. David Hedley, Department of Molecular Oncology, Ontario Cancer Institute (OCI).
Dr. Mark R.
